메뉴 건너뛰기




Volumn 49, Issue 6, 2017, Pages 782-783

Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE PLUS TAZOBACTAM; CREATININE; HYPERTENSIVE FACTOR; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; TAZOBACTAM;

EID: 85018867531     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.04.001     Document Type: Letter
Times cited : (41)

References (5)
  • 1
    • 84946567642 scopus 로고    scopus 로고
    • A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens
    • Bush, K., A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents 46 (2015), 483–493.
    • (2015) Int J Antimicrob Agents , vol.46 , pp. 483-493
    • Bush, K.1
  • 2
    • 84857646835 scopus 로고    scopus 로고
    • Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
    • Magiorakos, A.-P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18 (2012), 268–281.
    • (2012) Clin Microbiol Infect , vol.18 , pp. 268-281
    • Magiorakos, A.-P.1    Srinivasan, A.2    Carey, R.B.3    Carmeli, Y.4    Falagas, M.E.5    Giske, C.G.6
  • 3
    • 84929206762 scopus 로고    scopus 로고
    • Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)
    • Solomkin, J., Hershberger, E., Miller, B., Popejoy, M., Friedland, I., Steenbergen, J., et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 60 (2015), 1462–1471.
    • (2015) Clin Infect Dis , vol.60 , pp. 1462-1471
    • Solomkin, J.1    Hershberger, E.2    Miller, B.3    Popejoy, M.4    Friedland, I.5    Steenbergen, J.6
  • 4
    • 84929606496 scopus 로고    scopus 로고
    • Ceftolozane–tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
    • Wagenlehner, F.M., Umeh, O., Steenbergen, J., Yuan, G., Darouiche, R.O., Ceftolozane–tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet 385 (2015), 1949–1956.
    • (2015) Lancet , vol.385 , pp. 1949-1956
    • Wagenlehner, F.M.1    Umeh, O.2    Steenbergen, J.3    Yuan, G.4    Darouiche, R.O.5
  • 5
    • 84921029928 scopus 로고    scopus 로고
    • Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12)
    • Sader, H.S., Farrell, D.J., Castanheira, M., Flamm, R.K., Jones, R.N., Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother 69 (2014), 2713–2722.
    • (2014) J Antimicrob Chemother , vol.69 , pp. 2713-2722
    • Sader, H.S.1    Farrell, D.J.2    Castanheira, M.3    Flamm, R.K.4    Jones, R.N.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.